Category Archives: Muscular Dystrophy Treatment

AVI BioPharma Regains NASDAQ Compliance

BOTHELL, WA–(Marketwire -02/22/12)- AVI BioPharma, Inc. (NASDAQ: AVII – News), a developer of RNA-based therapeutics, announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, stating that the Company has regained compliance with NASDAQ's minimum $1.00 per share bid price requirement. The letter received noted that for 10 consecutive business days, from February 6, 2012 to February 17, 2012, the closing bid price of the Company's common stock was $1.00 per share or greater Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , | Comments Off

Ligand Licenses DARA Program to Retrophin

SAN DIEGO & NEW YORK–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND – News) and Retrophin, LLC announced that the companies have entered into an agreement in which Ligand has licensed rights to DARA (a Dual Acting Receptor Antagonist of Angiotensin and Endothelin receptors) to Retrophin. Under the terms of the agreement, Ligand will receive a net upfront payment of $1 million, and may receive, net of amounts owed to third parties, over $75 million in milestone payments based on clinical and regulatory progress as well as 9% in royalties on potential future worldwide sales by Retrophin. “DARA has the promise to be a significant medicine, and we are excited to partner with Retrophin to advance the development of the program and bring it closer to patients in need,” said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , | Comments Off

Cure Duchenne Announces Three New Funded Research Projects to Help Develop Treatments and Find a Cure for Duchenne …

Newport Beach, Calif., Feb. 21, 2012 (GLOBE NEWSWIRE) — CureDuchenne, a nonprofit organization that raises awareness and funds multiple research and development projects to cure Duchenne muscular dystrophy, announces the funding of three new research projects following its third annual CureDuchenne Scientific Summit. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , | Comments Off

Parent Project Muscular Dystrophy Awards $500,000 to Tivorsan Pharmaceuticals

To: HEALTH, MEDICAL AND NATIONAL EDITORS Grant Funds Work of Tivorsan Pharmaceuticals' Team to Bring Recombinant Biglycan to the Clinic for the Possible Treatment of Duchenne Muscular Dystrophy HACKENSACK, N.J., Feb. 21, 2012 /PRNewswire-USNewswire/ — Parent Project Muscular Dystrophy (PPMD) announced today that it will award Tivorsan Pharmaceuticals (Tivorsan) a $500,000 grant to develop the company's biglycan therapeutic candidate for Duchenne muscular dystrophy. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , , | Comments Off

Dateline Long Beach: The Aquatic Center brings swim therapy to disabled

Xiara Leiva, a swim instructor at the California Aquatic Therapy & Wellness Center in Long Beach, works with Joey Perez, l3, who has autism as well as muscular dystrophy and is terminally ill. (Sean Hiller / Staff Photographer) As instructors lift Joey from his wheelchair and place him in the warm pool water, a remarkable transformation takes place Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , | Comments Off

Medical clinics offer help for Big Island children

BY CHELSEA JENSEN WEST HAWAII TODAY cjensen@westhawaiitoday.com Shriners Hospital for Children is headed to the Big Island to connect pediatric doctors with young patients who need their specialized care. The Honolulu-based hospital, which serves Hawaii and the Asia and Pacific regions, will have outreach clinics at two West Hawaii locations Feb. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , , | Comments Off

When nerve meets muscle, biglycan seals the deal

The protein biglycan needs to be present to stabilize synapses at the neuromuscular junction after they have formed, according to research led by Brown University that appears in the Feb. 14, 2012, issue of the Journal of Neruoscience. “What neuromuscular junctions do second-by-second is essential for our brain to control movement and they are also important for the long-term health of both muscle and motor neurons,” said Justin Fallon, profesor of neuroscience at Brown University and the paper's senior author. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , , , , | Comments Off

JumpStart Invests $250,000 in Milo Biotechnology

CLEVELAND, Feb. 14, 2012 /PRNewswire/ – Milo Biotechnology will receive $250,000 from JumpStart Inc., a nonprofit investing intensive business assistance and some capital into early stage Northeast Ohio-based tech companies.  A clinical stage startup developing a therapy to increase muscle strength and improve the quality of life of muscular dystrophy patients, Milo is the 61st company in JumpStart's portfolio.  ”There are limited treatment options for muscular dystrophy and approved therapies are inadequate or can cause significant side effects,” says JumpStart's Mike Lang Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , | Comments Off

Amicus Therapeutics Awarded Grant From Muscular Dystrophy Association for Pompe Disease Program

CRANBURY, N.J. — Amicus Therapeutics , a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the receipt of a two-year, $186,000 grant from the Muscular … Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , , , | Comments Off

Alyssa Hansen | Mitt Romney takes on medical marijuana

Presidential GOP candidate Mitt Romney has explicitly expressed his dissension around medicinal marijuana in his campaign despite its numerous benefits. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , | Comments Off